FFA
SPRY icon

Farther Finance Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Farther Finance Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Buy
374
+9
+2% +$77 ﹤0.01% 5026
2026
Q1 		$2.96K Sell
365
-774
-68% -$7.42K ﹤0.01% 4747
2025
Q4 		$13.3K Sell
1,139
-401
-26% -$3.9K ﹤0.01% 3722
2025
Q3 		$15.5K Buy
1,540
+1,047
+212% +$15K ﹤0.01% 3197
2025
Q2 		$8.6K Sell
493
-43
-8% -$620 ﹤0.01% 3149
2025
Q1 		$6.72K Buy
536
+290
+118% +$3.49K ﹤0.01% 2919
2024
Q4 		$2.6K Buy
246
+240
+4,000% +$3.36K ﹤0.01% 2907
2024
Q3 		$87 Buy
+6
New +$71 ﹤0.01% 3804

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Farther Finance Advisors's SPRY Position: Q2 2026 in Review

Farther Finance Advisors increased its ARS Pharmaceuticals (SPRY) stake by 2.5% in Q2 2026, buying an estimated $77 and bringing the position to 374 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #5026.

Farther Finance Advisors first reported a position in SPRY in Q3 2024 and has held it in 8 quarters since. The position peaked at $15.5K in Q3 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Farther Finance Advisors held 374 shares of ARS Pharmaceuticals worth $3K as of Q2 2026.
  • Farther Finance Advisors bought 9 ARS Pharmaceuticals shares in Q2 2026, an estimated $77.
  • ARS Pharmaceuticals made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5026 holding.
  • Farther Finance Advisors first reported a position in ARS Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Farther Finance Advisors's ARS Pharmaceuticals position peaked at $15.5K in Q3 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.